Predicting GLP-1 Discontinuation From Pharmacy ClaimsByAayush Sisodia, MSHI, BDSPublished: August 6th 2026 | Updated: August 31st 2026
Impact of Automated Insulin Delivery on Type 2 Diabetes MeasuresByThomas W. Martens, MD,Bimal V. Patel, PharmD, MS,Sharon M. Wang, PharmD, MS,Laurel H. Messer, PhD, MPH, RN, CDCES, BC-ADM,Jordan E. Pinsker, MD,Daniel C. Malone, PhD, RPh,Miranda R. Polin, MS, BS,Diana I. Brixner, PhD, RPh,Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES,Osagie Ebekozien, MD, MPHJuly 23rd 2026
Geographical Access to Preferred Pharmacies in Medicare Part DByPinka Chatterji, PhD,Yiran Han, PhD,Chun-Yu Ho, PhDJuly 22nd 2026
Roles and Priorities Guiding Medicare Advantage Postacute Home Health ReferralsByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MAJuly 16th 2026
Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhDJuly 10th 2026